Sarwat Umer, MD
Rheumatology · Shreveport, LANPI 1871703108
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,612 of the $8,236 with a category attached, or 68.1%. 29 manufacturers reported payments, led by GSK at 39.6% of the total. Reporting peaked in 2021 at $2,642 and has fallen 68.2% since, to $839 in 2025. That places this record below the midpoint for rheumatology clinicians in LA, where the typical reported total is $8,351.
Across 299 payments — averaging $27.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Amgen$2K
- Genentech USA, Inc.$410
- Aurinia Pharma U.S., Inc.$399
- UCB, Inc.$331
- Johnson & Johnson$244
- plus $2K from 23 others
Across 23 payments — averaging $2596.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$43K
- EMD Serono, Inc.$16K
What the payments were for
- Consulting fees$2,53031%
- Food & beverage$5,61268%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 49 | $3,260 |
| Amgen | 103 | $1,864 |
| Genentech USA, Inc. | 24 | $410 |
| Aurinia Pharma U.S., Inc. | 20 | $399 |
| UCB, Inc. | 17 | $331 |
| Johnson & Johnson | 11 | $244 |
| Novartis | 9 | $209 |
| AstraZeneca | 13 | $203 |
| Boehringer Ingelheim | 7 | $201 |
| E.r. Squibb & Sons, L.L.C. | 6 | $164 |
| Sobi, Inc | 5 | $135 |
| Kyowa Kirin, Inc. | 5 | $106 |
| Pfizer | 6 | $105 |
| AbbVie | 3 | $100 |
| ANI Pharmaceuticals, Inc. | 3 | $95 |
| Mallinckrodt Hospital Products Inc. | 2 | $58 |
| Sanofi | 2 | $53 |
| Novo Nordisk | 2 | $47 |
| Janssen Scientific Affairs, LLC | 1 | $36 |
| Argenx US, Inc. | 1 | $27 |
| Travere Therapeutics, Inc. | 2 | $26 |
| Genentech, Inc. | 1 | $25 |
| Bayer | 1 | $23 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Octapharma USA, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$2,530
How this compares
$8,236 in reported general payments places this provider in the 45th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 86 | $592,560 |
| Enbrel SureclickEtanercept | 45 | $326,900 |
| BenlystaBelimumab | 26 | $135,428 |
| Humira(Cf)Adalimumab | 19 | $127,614 |
| Cosentyx SyringeSecukinumab | 12 | $86,467 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $82,977 |
| Mycophenolate Mofetil | 50 | $1,962 |
| Hydroxychloroquine Sulfate | 95 | $1,813 |
| MethotrexateMethotrexate Sodium | 106 | $1,434 |
| Sulfasalazine | 28 | $537 |
| Tramadol Hcl | 34 | $189 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $156 |
| Gabapentin | 23 | $142 |
| Prednisone | 29 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $3,260 | $135,42826 claims |
| AbbVieHumira(Cf) | $100 | $127,61419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Shreveport
- Aaron BroadwellShreveport$1.6M
- Frankie PedigoShreveport$98K
- Larry BroadwellShreveport$33K
- Mary WaltonShreveport$16K
- Mamatha KatikaneniShreveport$14K
- Robert GoodmanShreveport$14K
- Thomas PresslyShreveport$11K
- Kyla LokitzShreveport$7K
- Samina HayatShreveport$7K
- Mansi ShahShreveport$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.